Activation of Central Melanocortin Pathways by Fenfluramine

D-fenfluramine (d-FEN) was once widely prescribed and was among the most effective weight loss drugs, but was withdrawn from clinical use because of reports of cardiac complications in a subset of patients. Discerning the neurobiology underlying the anorexic action of d-FEN may facilitate the development of new drugs to prevent and treat obesity. Through a combination of functional neuroanatomy, feeding, and electrophysiology studies in rodents, we show that d-FEN–induced anorexia requires activation of central nervous system melanocortin pathways. These results provide a mechanistic explanation of d-FEN's anorexic actions and indicate that drugs targeting these downstream melanocortin pathways may prove to be effective and more selective anti-obesity treatments.

[1]  M. Low,et al.  Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus , 2001, Nature.

[2]  R. Cone,et al.  A Unique Metalolic Sysdrone Causes Obesity in the Melanocortin-3 Receptor-Deficient Mouse. , 2000, Endocrinology.

[3]  Yue Feng,et al.  Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass , 2000, Nature Genetics.

[4]  R. Cone,et al.  The central melanocortin system can directly regulate serum insulin levels. , 2000, Endocrinology.

[5]  Clifford B Saper,et al.  Leptin Differentially Regulates NPY and POMC Neurons Projecting to the Lateral Hypothalamic Area , 1999, Neuron.

[6]  L. Tecott,et al.  Reduced satiating effect of d-fenfluramine in serotonin 5-HT2C receptor mutant mice , 1999, Psychopharmacology.

[7]  C. Saper,et al.  From Lesions to Leptin Hypothalamic Control of Food Intake and Body Weight , 1999, Neuron.

[8]  C. Saper,et al.  Leptin Activates Hypothalamic CART Neurons Projecting to the Spinal Cord , 1998, Neuron.

[9]  S. O’Rahilly,et al.  A frameshift mutation in MC4R associated with dominantly inherited human obesity , 1998, Nature Genetics.

[10]  S. Cheetham,et al.  A comparison of the effects on central 5‐HT function of sibutramine hydrochloride and other weight‐modifying agents , 1998, British journal of pharmacology.

[11]  W. Edwards,et al.  Valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.

[12]  R. Cone,et al.  Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice , 1997, Cell.

[13]  Victor J. Hruby,et al.  Role of melanocortinergic neurons in feeding and the agouti obesity syndrome , 1997, Nature.

[14]  B. Guy-grand.  Clinical studies with dexfenfluramine: from past to future. , 1995, Obesity Research.

[15]  David Julius,et al.  Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors , 1995, Nature.

[16]  D. Wright,et al.  Comparative localization of serotonin1A, 1C, and 2 receptor subtype mRNAs in rat brain , 1995, The Journal of comparative neurology.

[17]  Richard P. Woychik,et al.  Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor , 1994, Nature.

[18]  N. Rowland,et al.  Dexfenfluramine induces fos-like immunoreactivity in discrete brain regions in rats , 1993, Brain Research Bulletin.

[19]  R. Woychik,et al.  Molecular characterization of the mouse agouti locus , 1992, Cell.

[20]  B. Guy-grand,et al.  INTERNATIONAL TRIAL OF LONG-TERM DEXFENFLURAMINE IN OBESITY , 1989, The Lancet.

[21]  T. Jessell,et al.  5-HT1c receptor is a prominent serotonin receptor subtype in the central nervous system. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[22]  C. Léránth,et al.  Serotoninergic endings on VIP-neurons in the suprachiasmatic nucleus and on ACTH-neurons in the arcuate nucleus of the rat hypothalamus. A combination of high resolution autoradiography and electron microscopic immunocytochemistry , 1984, Neuroscience Letters.

[23]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .